- Home
- ADAM vs SLS Comparison
ADAM vs SLS Comparison
Compare ADAM & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAM | SLS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | 221 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.0M | 706.7M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ADAM | SLS |
|---|---|---|
| Price | $8.69 | $5.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $9.17 | ★ $10.00 |
| AVG Volume (30 Days) | 768.9K | ★ 4.1M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.87% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.08 | $110.98 |
| P/E Ratio | $41.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.45 | $1.39 |
| 52 Week High | $9.32 | $6.14 |
Technical Indicators
Market Signals| Indicator | ADAM | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 63.55 | 54.63 |
| Support Level | $6.93 | $4.70 |
| Resistance Level | N/A | $5.28 |
| Average True Range (ATR) | 0.28 | 0.28 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 62.65 | 67.34 |
Price Performance
Historical ComparisonAbout ADAM Adamas Trust Inc.
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.